clinical trial · NCT06055959
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·recruiting·n = 8
Generalized Myasthenia GravisZilucoplan
brief summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
started
Oct 16, 2024
primary completion
Nov 16, 2026
completion
Dec 25, 2026
last updated
Apr 24, 2026
official title
A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol